| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Human epidermal growth factor receptor 2 in combined hepatocellular-cholangiocarcinoma: Prognostic and predictive guide for adjuvant chemotherapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ru-Yu Han, Yu-Kun Wei, Wei-Na Liu, Yi-Meng Wang, Tian-Qiang Song, Xiang-Dong Tian, Yu-Ren Xia, Lu Chen and Wen-Chen Gong |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82203423, 82373365 |
| the Beijing-Tianjin-Hebei Collaborative Innovation Special Project |
25242602D |
| the Tianjin Natural Science Foundation |
23JCYBJC00600 |
| Tianjin Key Medical Discipline Construction Project |
TJYXZDXK-3-003A and TJYXZDXK-3-016C |
| National Natural Science Foundation of China |
82403771, 82472991 |
| Joint Funds of the Natural Science Foundation, Tianjin |
25JCLMJC00720 |
|
| Corresponding Author |
Wen-Chen Gong, Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, West Huanhu Road, Ti Yuan Bei, Tianjin 300060, China. gongwenchen@tmu.edu.cn |
| Key Words |
Combined hepatocellular-cholangiocarcinoma; Human epidermal growth factor receptor 2; Tertiary lymphoid structures; Adjuvant chemotherapy; Prognosis; Surgical resection |
| Core Tip |
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare liver malignancy with poor prognosis and limited prognostic markers. This study shows that human epidermal growth factor receptor 2 (HER2) expression is an independent prognostic factor and is positively correlated with tertiary lymphoid structures. HER2 status also predicts differential response to adjuvant chemotherapy, with HER2-negative patients benefiting significantly while HER2-positive patients do not. These findings provide a rationale for using HER2 as a biomarker to guide postoperative treatment decisions and support precision stratification of adjuvant therapy in cHCC-CCA, offering practical implications for individualized patient management. |
| Publish Date |
2026-05-29 07:26 |
| Citation |
Han RY, Wei YK, Liu WN, Wang YM, Song TQ, Tian XD, Xia YR, Chen L, Gong WC. Human epidermal growth factor receptor 2 in combined hepatocellular-cholangiocarcinoma: Prognostic and predictive guide for adjuvant chemotherapy. World J Gastroenterol 2026; 32(22): 117417 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i22/117417.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i22.117417 |
